Moxifloxacin
Gestational Trophoblastic Neoplasm
OHSU Knight Cancer InstituteSmall moleculePhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 89/ 100
Competitive context
6 Active assets in the Gestational Trophoblastic Neoplasm cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Amifostine Gynecologic Oncology Group | Phase 3 | B |
Nivestim Fred Hutchinson Cancer Center | Phase 2 | B |
Alemtuzumab Fred Hutchinson Cancer Center | Phase 2 | B |
Tacrolimus Case Comprehensive Cancer Center | Phase 2 | B |
Sargramostim Cancer Treatment Centers of America | Phase 2 | B |
View all 25 →
Same molecule, other indications
Moxifloxacin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →